Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 737
  • Home
  • Print this page
  • Email this page

    Article Cited by others


Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer

Dine Jennifer, Gordon RuthAnn, Shames Yelena, Kasler Mary Kate, Barton-Burke Margaret

Year : 2017| Volume: 4| Issue : 2 | Page no: 127-135

   This article has been cited by
1 Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer
Marianne Davies,Emily Duffield
Clinical Journal of Oncology Nursing. 2020; 24(3): 277
[Pubmed]  [Google Scholar] [DOI]
2 The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy
Yuki Shinno,Yasushi Goto,Mayu Ohuchi,Akinobu Hamada,Hiroshi Nokihara,Yasuhiro Fujiwara,Yuichiro Ohe
JTO Clinical and Research Reports. 2020; 1(1): 100008
[Pubmed]  [Google Scholar] [DOI]
3 Oncolytic viruses: what to expect from their use in cancer treatment
Maria Terrível,Catarina Gromicho,Ana Miguel Matos
Microbiology and Immunology. 2020;
[Pubmed]  [Google Scholar] [DOI]
4 Hybrid phenotype mining method for investigating off-target protein and underlying side effects of anti-tumor immunotherapy
Yuyu Zheng,Xiangyu Meng,Pierre Zweigenbaum,Lingling Chen,Jingbo Xia
BMC Medical Informatics and Decision Making. 2020; 20(S3)
[Pubmed]  [Google Scholar] [DOI]
5 Cellular signalling pathways mediating the pathogenesis of chronic inflammatory respiratory diseases: an update
Meenu Mehta,Daljeet S. Dhanjal,Keshav R. Paudel,Bhupender Singh,Gaurav Gupta,S. Rajeshkumar,Lakshmi Thangavelu,Murtaza M. Tambuwala,Hamid A. Bakshi,Dinesh K. Chellappan,Parijat Pandey,Harish Dureja,Nitin B. Charbe,Sachin K. Singh,Shakti D. Shukla,Srinivas Nammi,Alaa A. Aljabali,Peter R. Wich,Philip M. Hansbro,Saurabh Satija,Kamal Dua
Inflammopharmacology. 2020;
[Pubmed]  [Google Scholar] [DOI]
6 Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials
Stéphane Faury,Jérôme Foucaud,Ali Montazeri
PLOS ONE. 2020; 15(1): e0227344
[Pubmed]  [Google Scholar] [DOI]
7 Recruiting monomer for dimer formation: resolving the antagonistic mechanisms of novel immune check point inhibitors against Programmed Death Ligand-1 in cancer immunotherapy
Opeyemi S. Soremekun,Fisayo A. Olotu,Clement Agoni,Mahmoud E. S. Soliman
Molecular Simulation. 2019; : 1
[Pubmed]  [Google Scholar] [DOI]
8 Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy,Chigozirim N. Ekeke,Kira L. Russell,Samuel C. Butler,Yue Wang,James D. Luketich,Adam C. Soloff,Rajeev Dhupar,Michael T. Lotze
OncoImmunology. 2019; : 1
[Pubmed]  [Google Scholar] [DOI]
9 Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers
Jitwadee Inthagard,Joanne Edwards,Antonia K. Roseweir
Clinical Science. 2019; 133(2): 181
[Pubmed]  [Google Scholar] [DOI]
10 Immunotherapy: last bullet in platinum refractory germ cell testicular cancer
Albert Semaan,Fady GH Haddad,Roland Eid,Hampig Raphael Kourie,Elie Nemr
Future Oncology. 2019; 15(5): 533
[Pubmed]  [Google Scholar] [DOI]
11 Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature
Spandana R. Kopalli,Tae-Bong Kang,Kwang-Ho Lee,Sushruta Koppula
Recent Patents on Anti-Cancer Drug Discovery. 2019; 14(2): 100
[Pubmed]  [Google Scholar] [DOI]
12 Preclinical Evaluation and Clinical Translation of Magnetite-Based Nanomedicines
Julia Nuzhina,Alexander A. Shtil,Artur Prilepskii,Vladimir V. Vinogradov
Journal of Drug Delivery Science and Technology. 2019; : 101282
[Pubmed]  [Google Scholar] [DOI]
13 Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Debarati Banik,Sara Moufarrij,Alejandro Villagra
International Journal of Molecular Sciences. 2019; 20(9): 2241
[Pubmed]  [Google Scholar] [DOI]
14 Effectiveness of Multi-Prognostic Index in older patients with advanced malignancies treated with immunotherapy
Andrea Sbrana,Rachele Antognoli,Giuseppe Pasqualetti,Giuseppe Linsalata,Chukwma Okoye,Valeria Calsolaro,Federico Paolieri,Francesco Bloise,Sergio Ricci,Andrea Antonuzzo,Fabio Monzani
Journal of Geriatric Oncology. 2019;
[Pubmed]  [Google Scholar] [DOI]
15 Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide
Lucia Feni,Sara Parente,Clémence Robert,Silvia Gazzola,Daniela Arosio,Umberto Piarulli,Ines Neundorf
Bioconjugate Chemistry. 2019;
[Pubmed]  [Google Scholar] [DOI]
16 Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma
James Lopez,Naveen Yarlagadda,Zaid Gheith,Meera Mohan,Appalanaidu Sasapu
Baylor University Medical Center Proceedings. 2019; : 1
[Pubmed]  [Google Scholar] [DOI]
17 Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy
Arash Urbina-Jara,Arash Rojas-Martinez,Arash Martinez-Ledesma,Arash Aguilar,Arash Villarreal-Garza,Arash Ortiz-Lopez
Genes. 2019; 10(10): 786
[Pubmed]  [Google Scholar] [DOI]
18 What can independent research for mesothelioma achieve to treat this orphan disease?
Alice Guazzelli,Parisa Meysami,Emyr Bakker,Ezio Bonanni,Constantinos Demonacos,Marija Krstic-Demonacos,Luciano Mutti
Expert Opinion on Investigational Drugs. 2019; : 1
[Pubmed]  [Google Scholar] [DOI]
19 Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer
Jin Sothornwit,Anakapong Phunmanee,Chatlert Pongchaiyakul
Frontiers in Endocrinology. 2019; 10
[Pubmed]  [Google Scholar] [DOI]
20 Tn antigen analogues: the synthetic way to “upgrade” an attracting tumour associated carbohydrate antigen (TACA)
Cristina Nativi,Francesco Papi,Stefano Roelens
Chemical Communications. 2019; 55(54): 7729
[Pubmed]  [Google Scholar] [DOI]
21 Iatrogenic CNS demyelination in the era of modern biologics
Neha Kumar,Hesham Abboud
Multiple Sclerosis Journal. 2019; 25(8): 1079
[Pubmed]  [Google Scholar] [DOI]
22 Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies
Shiao Li Oei,Anja Thronicke,Friedemann Schad
Evidence-Based Complementary and Alternative Medicine. 2019; 2019: 1
[Pubmed]  [Google Scholar] [DOI]
23 Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam,Vinay Prasad
JAMA Network Open. 2019; 2(5): e192535
[Pubmed]  [Google Scholar] [DOI]
24 Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments
Anusha Pusuluri,Debra Wu,Samir Mitragotri
Journal of Controlled Release. 2019;
[Pubmed]  [Google Scholar] [DOI]
25 Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy
Sri Murugan Poongkavithai Vadevoo,Smriti Gurung,Fatima Khan,Md. Enamul Haque,Gowri Rangaswamy Gunassekaran,Lianhua Chi,Uttapol Permpoon,Byungheon Lee
Archives of Pharmacal Research. 2019; 42(2): 150
[Pubmed]  [Google Scholar] [DOI]
26 Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy
Xinyu Ye,Xin Liang,Qian Chen,Qianwei Miao,Xiuli Chen,Xudong Zhang,Lin Mei
ACS Nano. 2019;
[Pubmed]  [Google Scholar] [DOI]
27 Immunotherapy in non-small cell lung cancer: The past, the present, and the future
Meng Lu,Yanjun Su
Thoracic Cancer. 2019;
[Pubmed]  [Google Scholar] [DOI]
28 Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy
Rama Soundararajan,Jared Fradette,Jessica Konen,Stacy Moulder,Xiang Zhang,Don Gibbons,Navin Varadarajan,Ignacio Wistuba,Debasish Tripathy,Chantale Bernatchez,Lauren Byers,Jeffrey Chang,Alejandro Contreras,Bora Lim,Edwin Parra,Emily Roarty,Jing Wang,Fei Yang,Michelle Barton,Jeffrey Rosen,Sendurai Mani
Cancers. 2019; 11(5): 714
[Pubmed]  [Google Scholar] [DOI]
29 A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity
Tim S. Grant,Darren Burns,Christopher Kiff,Dawn Lee
PharmacoEconomics. 2019;
[Pubmed]  [Google Scholar] [DOI]
30 A Case of Severe Seronegative Inflammatory Arthritis due to Nivolumab and Review of the Literature
Bicky Thapa,Asad Ali,Raunak Nair,Rishik Vashisht,Cassandra Calabrese
Case Reports in Rheumatology. 2019; 2019: 1
[Pubmed]  [Google Scholar] [DOI]
31 Immunology and Immunotherapy in Critical Care: An Overview
Nancy Munro
AACN Advanced Critical Care. 2019; 30(2): 113
[Pubmed]  [Google Scholar] [DOI]
32 Development of mRNA vaccines and their prophylactic and therapeutic applications
Kyuri Lee,Minjeong Kim,Yunmi Seo,Hyukjin Lee
Nano Research. 2018;
[Pubmed]  [Google Scholar] [DOI]
33 Therapeutic vaccines for high-risk HPV-associated diseases
Aleyo Chabeda,Romana J.R. Yanez,Renate Lamprecht,Ann E. Meyers,Edward P. Rybicki,Inga I. Hitzeroth
Papillomavirus Research. 2018; 5: 46
[Pubmed]  [Google Scholar] [DOI]
34 Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary
Julie R. Brahmer,Christina Lacchetti,John A. Thompson
Journal of Oncology Practice. 2018; 14(4): 247
[Pubmed]  [Google Scholar] [DOI]
35 A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity
Prabhakaran Kumar,Palash Bhattacharya,Bellur S. Prabhakar
Journal of Autoimmunity. 2018;
[Pubmed]  [Google Scholar] [DOI]
36 Addressing New Diagnostic and Treatment Challenges Associated With a New Age of Cancer Treatment
Jason J. Bischof,Carolyn J. Presley,Jeffrey M. Caterino
Annals of Emergency Medicine. 2018;
[Pubmed]  [Google Scholar] [DOI]
37 Immunotherapy Adverse Events, Part 2: The Role of the Primary Care Nurse Practitioner
Fedricker D. Barber
The Journal for Nurse Practitioners. 2018;
[Pubmed]  [Google Scholar] [DOI]
38 Guillain-Barré-like syndrome during pembrolizumab treatment
Stephanie Ong,James Chapman,Gavin Young,Talal Mansy
Muscle & Nerve. 2018;
[Pubmed]  [Google Scholar] [DOI]
39 Data-Driven Methods for Advancing Precision Oncology
Prema Nedungadi,Akshay Iyer,Georg Gutjahr,Jasmine Bhaskar,Asha B. Pillai
Current Pharmacology Reports. 2018;
[Pubmed]  [Google Scholar] [DOI]
40 Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment
Jialing Zhang,Stephan Stanislaw Späth,Sadie L Marjani,Wengeng Zhang,Xinghua Pan
Precision Clinical Medicine. 2018; 1(1): 29
[Pubmed]  [Google Scholar] [DOI]
41 Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo,Bhagirathbhai Dholaria,Aixa E. Soyano,Keith L. Knutson,Saranya Chumsri,Yanyan Lou
Journal of Hematology & Oncology. 2018; 11(1)
[Pubmed]  [Google Scholar] [DOI]
42 Ex Vivo Tumor-on-a-Chip Platforms to Study Intercellular Interactions within the Tumor Microenvironment
Vardhman Kumar,Shyni Varghese
Advanced Healthcare Materials. 2018; : 1801198
[Pubmed]  [Google Scholar] [DOI]
43 A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Ash Bullement,Yang Meng,Miranda Cooper,Dawn Lee,Tara Louise Harding,Chris O’Regan,Raquel Aguiar-Ibanez
Journal of Medical Economics. 2018; : 1
[Pubmed]  [Google Scholar] [DOI]
44 Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches
Nasser Hashemi Goradel,Nasir Mohajel,Ziba Veisi Malekshahi,Samira Jahangiri,Masoud Najafi,Bagher Farhood,Keywan Mortezaee,Babak Negahdari,Arash Arashkia
Journal of Cellular Physiology. 2018;
[Pubmed]  [Google Scholar] [DOI]
45 Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer,Christina Lacchetti,Bryan J. Schneider,Michael B. Atkins,Kelly J. Brassil,Jeffrey M. Caterino,Ian Chau,Marc S. Ernstoff,Jennifer M. Gardner,Pamela Ginex,Sigrun Hallmeyer,Jennifer Holter Chakrabarty,Natasha B. Leighl,Jennifer S. Mammen,David F. McDermott,Aung Naing,Loretta J. Nastoupil,Tanyanika Phillips,Laura D. Porter,Igor Puzanov,Cristina A. Reichner,Bianca D. Santomasso,Carole Seigel,Alexander Spira,Maria E. Suarez-Almazor,Yinghong Wang,Jeffrey S. Weber,Jedd D. Wolchok,John A. Thompson
Journal of Clinical Oncology. 2018; 36(17): 1714
[Pubmed]  [Google Scholar] [DOI]
46 Checkpoint inhibitors: What gastroenterologists need to know
Monjur Ahmed
World Journal of Gastroenterology. 2018; 24(48): 5433
[Pubmed]  [Google Scholar] [DOI]
47 Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
Seok-Ho Shin,Min-Ho Park,Jin-Ju Byeon,Byeong Lee,Yuri Park,Nahye Kim,Jangmi Choi,Young Shin
Pharmaceutics. 2018; 10(4): 260
[Pubmed]  [Google Scholar] [DOI]
48 Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study
Ash Bullement,Nicholas R. Latimer,Helen Bell Gorrod
Value in Health. 2018;
[Pubmed]  [Google Scholar] [DOI]
49 Diagnostik und Therapie von immunvermittelten Nebenwirkungen durch Checkpointinhibitoren in der Intensivmedizin
Y. d’Hargues,J. Prinz,P. Gödel,A. Shimabukuro-Vornhagen,M. Kochanek,B. Böll
Medizinische Klinik - Intensivmedizin und Notfallmedizin. 2018;
[Pubmed]  [Google Scholar] [DOI]
50 Nano-pulse stimulation induces potent immune responses, eradicating local breast cancer while reducing distant metastases
Siqi Guo,Yu Jing,Niculina I. Burcus,Brittany P. Lassiter,Royena Tanaz,Richard Heller,Stephen J. Beebe
International Journal of Cancer. 2017;
[Pubmed]  [Google Scholar] [DOI]


Read this article